Literature DB >> 17868340

Cell detachment modulates TRAIL resistance in ovarian cancer cells by downregulating the phosphatidylinositol 3-kinase/Akt pathway.

D Lane1, A Cartier, C Rancourt, A Piché.   

Abstract

TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is a potent inducer of apoptosis but many ovarian cancer cells display intrinsic resistance to TRAIL. The molecular determinants regulating TRAIL sensitivity in these resistant tumor cells are still incompletely understood. We observed that cell detachment enhances TRAIL-induced apoptosis in two TRAIL-resistant ovarian cancer cell lines. This process was accompanied by an increase of caspase activation, which could be blocked by caspase-8 inhibitor IETD. Cell detachment inhibited Akt phosphorylation. Phosphatidylinositol 3-kinase inhibition by LY294002 also enhanced TRAIL-induced apoptosis. Further decreased Akt activity by LY294002 in detached cells translated to increased cell death after TRAIL treatment. Our data indicate that cell detachment enhances TRAIL-induced killing by decreasing Akt activity in TRAIL-resistant ovarian carcinoma cells and suggest that Akt inhibition primes TRAIL-resistant cells to TRAIL-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17868340     DOI: 10.1111/j.1525-1438.2007.01062.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

1.  Targeted ovarian cancer treatment: the TRAILs of resistance.

Authors:  Nadzeya Goncharenko Khaider; Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

Review 2.  Metastasis suppressor function of tumor necrosis factor-related apoptosis-inducing ligand-R in mice: implications for TRAIL-based therapy in humans?

Authors:  Anne Grosse-Wilde; Christopher J Kemp
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

3.  TRAIL-coated leukocytes that prevent the bloodborne metastasis of prostate cancer.

Authors:  Elizabeth C Wayne; Siddarth Chandrasekaran; Michael J Mitchell; Maxine F Chan; Rachel E Lee; Chris B Schaffer; Michael R King
Journal:  J Control Release       Date:  2015-12-28       Impact factor: 9.776

4.  TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development.

Authors:  Anne Grosse-Wilde; Oksana Voloshanenko; S Lawrence Bailey; Gary M Longton; Uta Schaefer; Andreea I Csernok; Günther Schütz; Erich F Greiner; Christopher J Kemp; Henning Walczak
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

Review 5.  Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer.

Authors:  Ufuk Mert; Ahter Dilsad Sanlioglu
Journal:  Cell Mol Life Sci       Date:  2016-08-10       Impact factor: 9.261

6.  TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids.

Authors:  Siddarth Chandrasekaran; Jocelyn R Marshall; James A Messing; Jong-Wei Hsu; Michael R King
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

7.  The Anti-Proliferative Effect of PI3K/mTOR and ERK Inhibition in Monolayer and Three-Dimensional Ovarian Cancer Cell Models.

Authors:  Elizabeth Dunn; Kenny Chitcholtan; Peter Sykes; Ashley Garrill
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.